Hefei Lifeon Pharmaceutical Co., Ltd. Share Price

Equities

003020

CNE100004BD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 10/05/2024 am IST 5-day change 1st Jan Change
25.3 CNY -0.47% Intraday chart for Hefei Lifeon Pharmaceutical Co., Ltd. +7.07% -10.12%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 1.52B 210M 17.56B Sales 2025 * 1.82B 252M 21.05B Capitalization 4.04B 559M 46.69B
Net income 2024 * 285M 39.44M 3.29B Net income 2025 * 336M 46.5M 3.88B EV / Sales 2024 * 2.66 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.22 x
P/E ratio 2024 *
14.2 x
P/E ratio 2025 *
12 x
Employees 1,315
Yield 2024 *
2.11%
Yield 2025 *
2.31%
Free-Float 35.48%
More Fundamentals * Assessed data
Dynamic Chart
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lifeon Pharma’s Diabetes Drugs Pass China Consistency Evaluation MT
Certain A Shares of Hefei Lifeon Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023. CI
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate MT
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director CI
Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd.(XSEC:003020) added to S&P Global BMI Index CI
Hefei Lifeon Pharmaceutical Co., Ltd. signed equity transfer agreement to acquire 51% stake in Anhui Joyfar Pharmaceutical Co. Ltd. from Beijing Huixu Jintong Investment Center (Limited Partnership), Beijing Huixu Jintai Investment Center (Limited Partnership), Gong Tonglin, Shen Jun, Zhao Shoutian and Ouyang Hanlin for approximately CNY 220 million. CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022 CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-0.47%
1 week+7.07%
Current month+7.07%
1 month+18.61%
3 months+21.46%
6 months-10.57%
Current year-10.12%
More quotes
1 week
23.35
Extreme 23.35
25.98
1 month
18.65
Extreme 18.65
25.98
Current year
16.49
Extreme 16.49
28.65
1 year
16.49
Extreme 16.49
44.66
3 years
16.49
Extreme 16.49
44.66
5 years
16.43
Extreme 16.426
44.66
10 years
16.43
Extreme 16.426
44.66
More quotes
Managers TitleAgeSince
Founder 60 16/02/16
Director of Finance/CFO 48 01/10/01
Chief Tech/Sci/R&D Officer 62 01/05/01
Members of the board TitleAgeSince
Director/Board Member 61 15/17/15
Director/Board Member 58 23/20/23
Founder 63 16/02/16
More insiders
Date Price Change Volume
10/24/10 25.3 -0.47% 1 549 990
09/24/09 25.42 -0.24% 2,042,076
08/24/08 25.48 +1.23% 3,589,451
07/24/07 25.17 +4.88% 5,257,354
06/24/06 24 +1.57% 4,383,194

End-of-day quote Shenzhen S.E., May 10, 2024

More quotes
Hefei Lifeon Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical preparations and active pharmaceutical ingredients (APIs). The Company is also engaged in the wholesale and retailing of pharmaceuticals and medical devices. The Company's main products involve cardiovascular drugs, digestive system drugs and skin topical drugs.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
25.3
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 003020 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW